Skip to main content
Home / Current Opinion in Pulmonary Medicine, Volume 27, Number 3

Host-directed therapies for COVID-19

Buy Article:

$57.00 + tax (Refund Policy)

Authors: Maeurer, Markus 1 ; Ramalho, Renata 2 ; Wang, Fu-Sheng 3 ; Zumla, Alimuddin 4 ; 

Source: Current Opinion in Pulmonary Medicine, Volume 27, Number 3, 1 May 2021, pp. 205-209(5)

Publisher: Wolters Kluwer

DOI: https://doi.org/10.1097/MCP.0000000000000769

Purpose of review

Severe acute respiratory syndrome coronavirus-2-induced hyperinflammation is a major cause of death or end-organ dysfunction in COVID-19 patients. We review adjunct host-directed therapies (HDTs) for COVID-19 management.

Recent findings

The use of umbilical cord-derived mesenchymal stem cells as HDT for COVID-19 has been shown to be safe in phase 1 and 2 trials. Trials of anti-interleukin-6 receptor antibodies show promising mortality benefit in hospitalized COVID-19 patients. Repurposed drugs and monoclonal antibodies targeting specific cytokines acting on different aspects of the pro- and anti-inflammatory cascades are under evaluation.Summary

A range of HDTs shows promise for reducing mortality and improving long term disability in patients with severe COVID-19, and require evaluation in randomized, controlled trials

Keywords: COVID-19; host-directed therapies; interleukins; mesenchymal stem cells; severe acute respiratory syndrome coronavirus-2

Document Type: Research Article

Affiliations: 1: ImmunoSurgery Unit, Champalimaud Centre for the Unknown, Lisbon, Portugal, I Medizinische Klinik, Johannes Gutenberg University Mainz, Germany 2: Egas Moniz Higher Education School, Instituto Universitário Egas Moniz, Centro de Investigação Interdisciplinar Egas Moniz (CiiEM, U4585-FCT), Applied Nutrition Studies Group (G.E.N.A.-IUEM), Monte de Caparica, Portugal 3: Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China 4: Department of Infection, Division of Infection and Immunity, University College London, and National Institutes of Health and Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK

Publication date: 01 May 2021

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content